DACS
BMRN icon

Dymon Asia Capital (Singapore)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Dymon Asia Capital (Singapore)’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$629K Hold
11,000
– – 0.03% 189
2026
Q1 		$621K Buy
+11,000
New +$641K 0.06% 204

Other funds holding BMRN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
AIM
ARGA Investment Management Stamford, Connecticut $3.92B AUM 35.93% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Dymon Asia Capital (Singapore)'s BMRN Position: Q2 2026 in Review

Dymon Asia Capital (Singapore) held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 11,000 shares worth $629K. The position accounts for 0.03% of the portfolio, ranked #189.

Dymon Asia Capital (Singapore) first reported a position in BMRN in Q1 2026 and has held it in 2 quarters since. 178 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Dymon Asia Capital (Singapore) held 11,000 shares of BioMarin Pharmaceuticals worth $629K as of Q2 2026.
  • Dymon Asia Capital (Singapore) left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
  • BioMarin Pharmaceuticals made up 0.03% of Dymon Asia Capital (Singapore)'s portfolio in Q2 2026, its #189 holding.
  • Dymon Asia Capital (Singapore) first reported a position in BioMarin Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 178 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Dymon Asia Capital (Singapore)'s 13F filing for Q2 2026, filed 23 Jul 2026.